Literature DB >> 8779458

The emergence of Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in Cleveland, Ohio: epidemiology and risk factors.

S M Gordon1, C J Carlyn, L J Doyle, C C Knapp, D L Longworth, G S Hall, J A Washington.   

Abstract

BACKGROUND: Until 1992, almost all strains of Neisseria gonorrhoeae that had been tested in the United States were susceptible to fluoroquinolones, including ciprofloxacin. However, among men with urethral gonococcal infections who attended one sexually transmitted disease clinic in Cleveland, Ohio, the prevalence of gonococci with decreased susceptibility to ciprofloxacin increased from 2% in 1991 to 16% in 1994.
OBJECTIVE: To describe the emergence of and risk factors for gonococcal urethritis caused by gonococci with decreased susceptibility to ciprofloxacin. Resistance to ciprofloxacin was considered to be decreased if the mean inhibitory concentration was at least 0.12 microgram/mL, and was less than or equal to 0.25 microgram/mL; this definition did not equate with the definition of clinical resistance.
DESIGN: Case-control study.
SETTING: An urban sexually transmitted disease clinic. PARTICIPANTS: 51 case-patients and 106 controls. MEASUREMENTS: Pulsed-field gel electrophoresis was used to identify individual genotypes of ciprofloxacin-resistant and ciprofloxacin-susceptible isolates.
RESULTS: 55 of the 746 isolates of N. gonorrhoeae that were tested (7.4%) had decreased susceptibility to ciprofloxacin, and the prevalence of N. gonorrhoeae with decreased susceptibility significantly increased during the study period. Case-patients were significantly less likely to have gram-negative diplococci seen on microscopic examination of urethral discharge (P < or = 0.01) and were less likely to be treated for gonococcal urethritis than were controls (P < or = 0.001). Molecular typing suggested the spread of a single genotype of N. gonorrhoeae.
CONCLUSIONS: Strains of gonococci with decreased susceptibility to ciprofloxacin appear to have become endemic in Cleveland, Ohio. The clinical significance of these isolates is not clear, but the potential for the emergence of clinically important resistance may preclude the use of fluoroquinolones as an alternative treatment for uncomplicated gonorrhea.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8779458     DOI: 10.7326/0003-4819-125-6-199609150-00006

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  7 in total

1.  Characterization of Neisseria gonorrhoeae strains with decreased susceptibility to fluoroquinolones isolated in Greece from 1996 to 1999.

Authors:  A Mavroidi; L S Tzouvelekis; P T Tassios; A Flemetakis; M Daniilidou; E Tzelepi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

Review 2.  Quinolones in sexually transmitted diseases: state of the art.

Authors:  G L Ridgway
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 3.  Concurrent gonococcal and chlamydial infection: how best to treat.

Authors:  A J Robinson; G L Ridgway
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

Review 4.  Practical recommendations for the drug treatment of bacterial infections of the male genital tract including urethritis, epididymitis and prostatitis.

Authors:  M L Joly-Guillou; S Lasry
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

5.  Quinolone Resistance in Neisseria gonorrhoeae.

Authors:  Janine R. Tompkins; Jonathan M. Zenilman
Journal:  Curr Infect Dis Rep       Date:  2001-04       Impact factor: 3.725

Review 6.  Fluoroquinolone resistance in Neisseria gonorrhoeae.

Authors:  J S Knapp; K K Fox; D L Trees; W L Whittington
Journal:  Emerg Infect Dis       Date:  1997 Jan-Mar       Impact factor: 6.883

Review 7.  Emerging mechanisms of fluoroquinolone resistance.

Authors:  D C Hooper
Journal:  Emerg Infect Dis       Date:  2001 Mar-Apr       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.